[Results] 36 weeks, 9kg, and oral GLP-1 was the hard part
36 weeks, 9kg, and oral GLP-1 was the hard part. This is a description of what happened to me and not a plan for anybody else.
Numbers, in the order they matter: 36 weeks and 9kg.
Read both programme names carefully after mixing them up in a comment and being politely corrected.
The no-timing-restriction thing is the part I would care about most in practice, and it barely gets mentioned here.
Screenshot none of this. Read the whole thread, including the parts where I am told I am wrong.
best — the order this archive was captured in
Why "oral" is doing two completely different jobs in the sentences people write here.
Oral semaglutide is a peptide co-formulated with an absorption enhancer, which is why it comes with food and water timing requirements. This compound is a non-peptide small molecule that activates the same receptor, formulated as an ordinary tablet.
The practical consequences differ enormously: no timing constraints, a conventional manufacturing route, different stability behaviour, and a different analytical problem for anybody trying to verify identity or purity. Whenever a thread here compares the two, check which sense of "oral" each half is using.
Holding off on any opinion until phase 3 reports. That is not a satisfying position and it is the honest one.
[removed by moderator]
Assumed the peptide purity conversations transferred and they do not. Different analytical problem entirely.
What did the tolerability table look like at that dose?
Assumed the peptide purity conversations transferred and they do not.
This is the fact the whole board hangs on. Small molecule, not peptide.
a non-peptide agonist does not degrade the way a peptide does
Spent an evening reading about small-molecule agonism at a peptide receptor. Genuinely interesting engineering.
Is that from the publication or the press release?
Compared milligram figures across two completely different molecule classes in a comment. Deserved the correction.
It is a non-peptide small-molecule agonist at the GLP-1 receptor. That is a substantial medicinal chemistry achievement: getting a small molecule to activate a receptor evolved for a peptide ligand.
Correcting myself: that was a phase 2 readout and I described it as phase 3.